Urology
Volume 75, Issue 1 , Pages 143-147 , January 2010

Resistive Index: A Newly Identified Predictor of Outcome of Transurethral Prostatectomy in Patients With Benign Prostatic Hyperplasia

Received 25 April 2009 ,Accepted 6 August 2009.

References 

  1. Mebust WK. Transurethral prostatectomy. Urol Clin North Am. 1990;17:575–585
  2. Rifkin MD, Sudakoff GS, Alexander AA. Prostate: techniques, results, and potential applications of color Doppler US scanning. Radiology. 1993;186:509–513
  3. Neumaier CE, Martinoli C, Derchi LE, et al. Normal prostate gland: examination with color Doppler US. Radiology. 1995;196:453–457
  4. Kojima M, Watanabe H, Watanabe M, et al. Preliminary results of power Doppler imaging in benign prostatic hyperplasia. Ultrasound Med Biol. 1997;23:1305–1309
  5. Kojima M, Ochiai A, Naya Y, et al. Doppler resistive index in benign prostatic hyperplasia: correlation with ultrasonic appearance of the prostate and infravesical obstruction. Eur Urol. 2000;37:436–442
  6. Tsuru N, Kurita Y, Masuda H, et al. Role of Doppler ultrasound and resistive index in benign prostatic quantification of voiding dysfunction in patients awaiting transurethral prostatectomy. Int J Urol. 2002;9:427–430
  7. Tsuru N, Kurita Y, Suzuki K, et al. Resistance index in benign prostatic hyperplasia using power Doppler imaging and clinical outcomes after transurethral vaporization of the prostate. Int J Urol. 2005;12:264–269
  8. Homma Y, Kawabe K, Tsukamoto T, et al. Estimate criteria for efficacy of treatment in benign prostatic hyperplasia. Int J Urol. 1996;3:267–273
  9. Barry MJ, Girman CJ, O'Leary MP, et al. Using repeated measures of symptom score, uroflowmetry and prostate specific antigen in the clinical management of prostate disease (Benign Prostatic Hyperplasia Treatment Outcomes Study Group). J Urol. 1995;153:99–103
  10. Javlé P, Jenkins SA, West C, et al. Quantification of voiding dysfunction in patients awaiting transurethral prostatectomy. J Urol. 1996;156:1014–1018
  11. Kranse R, van Mastrigt R. Relative bladder outlet obstruction. J Urol. 2002;168:565–570
  12. Greene DR, Egawa S, Hellerstein DK, et al. Sonographic measurements of transition zone of prostate in men with and without benign prostatic hyperplasia. Urology. 1990;36:293–299
  13. Kaplan SA, Te AE, Pressler LB, et al. Transition zone index as a method of assessing benign prostatic hyperplasia: correlation with symptoms, urine flow and detrusor pressure. J Urol. 1995;154:1764–1769
  14. Kurita Y, Masuda H, Terada H, et al. Transition zone index as a risk factor for acute urinary retention in benign prostatic hyperplasia. Urology. 1998;51:595–600
  15. Desai MM. Transrectal ultrasound parameters: presumed circle area ratio and transitional zone area in the evaluation of patients with lower urinary tract symptoms. J Endourol. 1999;13:317–321
  16. Norris CS, Pfeiffer JS, Rittgers SE, et al. Noninvasive evaluation of renal artery stenosis and renovascular resistance. J Vasc Surg. 1984;1:192–201
  17. Spencer JAD, Giussani DA, Moore PJ, et al. In vitro validation of Doppler indices using blood and water. J Ultrasound Med. 1991;10:305–308
  18. Ozdemir H, Onur R, Bozgeyik Z, et al. Measuring resistance index in patients with BPH and lower urinary tract symptoms. J Clin Ultrasound. 2005;33:176–180
  19. Berger AP, Deibl M, Leonhartsberger N, et al. Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction. BJU Int. 2005;96:1073–1078
  20. Berger AP, Bartsch G, Deibl M, et al. Atherosclerosis as a risk factor for benign prostatic hyperplasia. BJU Int. 2006;98:1038–1042
  21. Halpern EJ, Frauscher F, Forsberg F, et al. High-frequency Doppler US of the prostate: effect of the patient position. Radiology. 2002;222:634–639

PII: S0090-4295(09)02345-0

doi: 10.1016/j.urology.2009.08.017

Urology
Volume 75, Issue 1 , Pages 143-147 , January 2010

Article Tools

* Image Usage & Resolution